Catalent, Inc. (CTLT)

$59.66

+0.66

(+1.12%)▲

Market is closed - opens 8 PM, 22 Nov 2024

Performance

  • $58.92
    $59.84
    $59.66
    downward going graph

    1.25%

    Downside

    Day's Volatility :1.55%

    Upside

    0.3%

    downward going graph
  • $36.74
    $61.20
    $59.66
    downward going graph

    38.42%

    Downside

    52 Weeks Volatility :39.97%

    Upside

    2.52%

    downward going graph

Returns

PeriodCatalent, Inc.Sector (Health Care)S&P500
3 Months
-0.69%
-7.6%
5.3%
6 Months
7.35%
-2.3%
11.2%
1 Year
48.09%
10.1%
30.4%
3 Years
-54.14%
7.5%
26.0%

Highlights

Market Capitalization
10.7B
Book Value
$19.52
Earnings Per Share (EPS)
-2.28
PEG Ratio
2.95
Wall Street Target Price
63.429
Profit Margin
-9.34%
Operating Margin TTM
-6.94%
Return On Assets TTM
-0.18%
Return On Equity TTM
-11.19%
Revenue TTM
4.4B
Revenue Per Share TTM
24.4
Quarterly Revenue Growth YOY
4.2%
Gross Profit TTM
1.0B
EBITDA
462.0M
Diluted Eps TTM
-2.28
Quarterly Earnings Growth YOY
-0.15
EPS Estimate Current Year
0.2
EPS Estimate Next Year
1.13
EPS Estimate Current Quarter
0.05
EPS Estimate Next Quarter
0.19

Analyst Recommendation

Hold
    41%Buy
    58%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Catalent, Inc.(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
12
Hold
10
11
10
Sell
00
00
1

Analyst Forecast

What analysts predicted

Upside of 6.32%

Current $59.66
Target $63.43

Company Financials

FY19Y/Y Change
Revenue
2.5B
↑ 2.22%
Net Income
137.4M
↑ 64.35%
Net Profit Margin
5.46%
↑ 2.07%
FY20Y/Y Change
Revenue
3.1B
↑ 22.89%
Net Income
173.0M
↑ 25.91%
Net Profit Margin
5.59%
↑ 0.13%
FY21Y/Y Change
Revenue
4.0B
↑ 29.21%
Net Income
585.0M
↑ 238.15%
Net Profit Margin
14.63%
↑ 9.04%
FY22Y/Y Change
Revenue
4.8B
↑ 20.76%
Net Income
499.0M
↓ 14.7%
Net Profit Margin
10.34%
↓ 4.29%
FY23Y/Y Change
Revenue
4.3B
↓ 11.43%
Net Income
-232.0M
↓ 146.49%
Net Profit Margin
-5.43%
↓ 15.77%
FY24Y/Y Change
Revenue
4.4B
↑ 2.46%
Net Income
-1.0B
↑ 349.57%
Net Profit Margin
-23.81%
↓ 18.38%
Q2 FY23Q/Q Change
Revenue
1.1B
↑ 2.99%
Net Income
-86.0M
↓ 62.11%
Net Profit Margin
-8.05%
↑ 13.84%
Q3 FY23Q/Q Change
Revenue
982.0M
↓ 8.05%
Net Income
-715.0M
↑ 731.4%
Net Profit Margin
-72.81%
↓ 64.76%
Q4 FY23Q/Q Change
Revenue
1.0B
↑ 4.28%
Net Income
-206.0M
↓ 71.19%
Net Profit Margin
-20.12%
↑ 52.69%
Q1 FY24Q/Q Change
Revenue
1.1B
↑ 4.88%
Net Income
-101.0M
↓ 50.97%
Net Profit Margin
-9.4%
↑ 10.72%
Q2 FY24Q/Q Change
Revenue
1.3B
↑ 21.14%
Net Income
23.0M
↓ 122.77%
Net Profit Margin
1.77%
↑ 11.17%
Q3 FY24Q/Q Change
Revenue
1.0B
↓ 21.37%
Net Income
-129.0M
↓ 660.87%
Net Profit Margin
-12.61%
↓ 14.38%
FY19Y/Y Change
Total Assets
6.2B
↑ 36.48%
Total Liabilities
4.5B
↑ 30.72%
FY20Y/Y Change
Total Assets
7.8B
↑ 25.75%
Total Liabilities
4.9B
↑ 8.34%
FY21Y/Y Change
Total Assets
9.1B
↑ 17.17%
Total Liabilities
5.2B
↑ 6.55%
FY22Y/Y Change
Total Assets
10.5B
↑ 15.31%
Total Liabilities
5.7B
↑ 9.91%
FY23Y/Y Change
Total Assets
10.8B
↑ 2.62%
Total Liabilities
6.1B
↑ 7.62%
FY24Y/Y Change
Total Assets
9.8B
↓ 9.54%
Total Liabilities
6.1B
↑ 0.03%
Q2 FY23Q/Q Change
Total Assets
10.8B
↓ 0.44%
Total Liabilities
6.1B
↑ 0.33%
Q3 FY23Q/Q Change
Total Assets
10.0B
↓ 6.83%
Total Liabilities
6.1B
↓ 0.1%
Q4 FY23Q/Q Change
Total Assets
10.0B
↓ 0.58%
Total Liabilities
6.3B
↑ 2.61%
Q1 FY24Q/Q Change
Total Assets
9.9B
↓ 1.09%
Total Liabilities
6.3B
↓ 0.52%
Q2 FY24Q/Q Change
Total Assets
9.8B
↓ 1.28%
Total Liabilities
6.1B
↓ 1.9%
Q3 FY24Q/Q Change
Total Assets
9.7B
↓ 0.46%
Total Liabilities
6.2B
↑ 0.28%
FY19Y/Y Change
Operating Cash Flow
247.7M
↓ 33.86%
Investing Cash Flow
-1.5B
↑ 64.3%
Financing Cash Flow
1.2B
↑ 79.55%
FY20Y/Y Change
Operating Cash Flow
440.3M
↑ 77.76%
Investing Cash Flow
-827.5M
↓ 45.21%
Financing Cash Flow
1.0B
↓ 16.62%
FY21Y/Y Change
Operating Cash Flow
433.0M
↓ 1.66%
Investing Cash Flow
-649.0M
↓ 21.57%
Financing Cash Flow
142.0M
↓ 85.82%
FY22Y/Y Change
Operating Cash Flow
439.0M
↑ 1.39%
Investing Cash Flow
-1.9B
↑ 190.29%
Financing Cash Flow
1.0B
↑ 626.06%
FY23Y/Y Change
Operating Cash Flow
261.0M
↓ 40.55%
Investing Cash Flow
-1.9B
↑ 0.0%
Financing Cash Flow
521.0M
↓ 49.47%
Q2 FY23Q/Q Change
Operating Cash Flow
203.0M
↓ 417.19%
Investing Cash Flow
-128.0M
↑ 16.36%
Financing Cash Flow
-51.0M
↑ 104.0%
Q3 FY23Q/Q Change
Operating Cash Flow
-70.0M
↓ 134.48%
Investing Cash Flow
-84.0M
↓ 34.37%
Financing Cash Flow
98.0M
↓ 292.16%

Technicals Summary

Sell

Neutral

Buy

Catalent, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Catalent, Inc.
Catalent, Inc.
-1.96%
7.35%
48.09%
-54.14%
14.45%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
5.76%
-12.28%
12.48%
43.36%
8.39%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-5.01%
11.27%
13.94%
27.94%
27.94%
Zoetis Inc.
Zoetis Inc.
-7.27%
1.67%
-1.71%
-21.69%
46.12%
Viatris Inc.
Viatris Inc.
13.48%
19.8%
39.98%
0.08%
-19.65%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.95
0.2
-0.11
0.0
NA
19.52
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
31.77
32.88
0.28
6.54
0.16
0.12
NA
26.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.58
28.73
1.69
0.34
0.07
0.04
0.02
1.82
Zoetis Inc.
Zoetis Inc.
33.0
33.0
2.46
5.87
0.47
0.15
0.01
11.59
Viatris Inc.
Viatris Inc.
224.4
NA
0.08
2.67
-0.04
0.02
0.04
16.58
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Catalent, Inc.
Catalent, Inc.
Hold
$10.7B
14.45%
211.02
-9.34%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$12.1B
8.39%
31.77
17.21%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$42.6B
27.94%
28.58
10.75%
Zoetis Inc.
Zoetis Inc.
Buy
$79.2B
46.12%
33.0
26.55%
Viatris Inc.
Viatris Inc.
Hold
$15.1B
-19.65%
224.4
-5.87%

Institutional Holdings

  • Vanguard Group Inc

    11.15%

  • BlackRock Inc

    8.46%

  • Nomura Holdings Inc

    6.06%

  • State Street Corp

    4.04%

  • Capital World Investors

    3.53%

  • Barclays PLC

    2.74%

Company Information

catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p

Organization
Catalent, Inc.
Employees
17000
CEO
Mr. John J. Greisch M.B.A.
Industry
Health Technology

FAQs